Benzinga - Gainers
- Super League Gaming, Inc. (NASDAQ: SLGG) jumped 119.8% to $0.9408 in pre-market trading. LandVault and Super League disclosed a strategic partnership to provide brands with scalable solutions to bridge the gap between Web2 and Web3.
- BELLUS Health Inc. (NASDAQ: BLU) gained 97.5% to $14.34 in pre-market trading after GSK agreed to acquire the company for $14.75 per share in cash representing an approximate total equity value of $2 billion (£1.6 billion).
- TC Biopharm (Holdings) Plc (NASDAQ: TCBP) surged 59.4% to $2.55 in pre-market trading after jumping 15% on Monday. TC BioPharm recently announced closing of $5.5 million public offering.
- Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares climbed 59.4% to $2.52 in pre-market trading after jumping 25% on Monday.
- Gamida Cell Ltd. (NASDAQ: GMDA) climbed 40.2% to $1.57 in pre-market trading after the U.S. Food and Drug Administration approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv).
- Altamira Therapeutics Ltd. (NASDAQ: CYTO) gained 27.3% to $1.40 in pre-market trading. Altamira Therapeutics recently announced the publication of results from its Phase 2 trial with AM-125 in acute vestibular syndrome in a leading peer reviewed journal..
- Ideanomics, Inc. (NASDAQ: IDEX) gained 20.9% to $0.0676 in pre-market trading after dropping 26% on Monday.
- Avenue Therapeutics, Inc. (NASDAQ: ATXI) gained 17.1% to $1.35 in pre-market trading after the company announced a regulatory update based on Type C meeting with the FDA and next steps in development of IV Tramadol.
- Innovid Corp. (NYSE: CTV) gained 15.2% to $1.21 in pre-market trading after gaining 25% on Monday. Innovid increased its Q1 revenue guidance to $30 million.
- Bed Bath & Beyond Inc. (NASDAQ: BBBY) climbed 12.1% to $0.3140 in pre-market trading after gaining around 18% on Monday. Bed Bath & Beyond recently filed preliminary prospectus for resale of up to 111.7 million shares of common stock by B. Riley Principal Capital II.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) fell 27.8% to $0.4110 in pre-market trading after jumping around 103% on Monday. Bellicum Pharmaceuticals recently discontinued Phase 1/2 trials and initiated an evaluation of strategic alternatives.
- ContraFect Corporation (NASDAQ: CFRX) shares dropped 24.9% to $1.72 in pre-market trading after surging 154% on Monday. ContraFect recently announced initiation of a Phase 1b/2 study of exebacase in patients with chronic prosthetic joint infections of the knee.
- Presto Automation Inc. (NASDAQ: PRST) fell 20.4% to $2.88 in pre-market trading after jumping over 158% on Monday. Presto recently promoted Dan Mosher to President and Xavier Casanova to Chief Operating Officer.
- KWESST Micro Systems Inc. (NASDAQ: KWE) fell 19.4% to $2.49 in pre-market after gaining 18% on Monday.
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) fell 17.8% to $2.26 in pre-market trading after surging 17% on Monday.
- Windtree Therapeutics, Inc. (NASDAQ: WINT) fell 16.6% to $6.90 in pre-market trading. Windtree Therapeutics shares surged 91% on Monday after the company announced the European Patent Office has granted Patent No. 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
- Oblong, Inc. (NASDAQ: OBLG) fell 16.4% to $1.79 in pre-market trading after dropping more than 20% on Monday.
- Blackboxstocks Inc. (NASDAQ: BLBX) fell 16.1% to $4.59 in pre-market trading. Blackboxstocks shares jumped 106% on Monday after the company announced it entered a letter of intent to merge with Evtec.
- Digital Brands Group, Inc. (NASDAQ: DBGI) fell 15.7% to $1.23 in pre-market trading following Q4 results. Digital Brands Group posted a Q4 loss of $20.46 per share.
- AEye, Inc. (NASDAQ: LIDR) shares fell 12.8% to $0.2792 in pre-market trading after climbing 35% on Monday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.